Wendye Robbins - 31 Mar 2025 Form 4 Insider Report for RAPT Therapeutics, Inc. (RAPT)

Reporting relationship: Director
Issuer ticker: RAPT
Reported as of: 31 Mar 2025
Net transaction value: +$52,502
SEC form: 4
Accepted by SEC: 02 Apr 2025, 21:08:06 UTC
Prior SEC filing: 23 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Rodney Young, Attorney-in-Fact

Key filing fact

Wendye Robbins filed Form 4 for RAPT Therapeutics, Inc. (RAPT) on 02 Apr 2025.

Key facts

This page summarizes Wendye Robbins's Form 4 filing for RAPT Therapeutics, Inc. (RAPT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2025, 21:08.

Change

Previous filing in this sequence was filed on 23 May 2024.
Current net transaction value: +$52,502.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPT transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $52,502
Shares: +49,432
Change %
Price: $1.06
Shares after: 49,432
Date: 31 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,432
Exercise price: $1.22
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2025 with the first installment vesting on March 31, 2025, provided that the reporting person is in service as a director on the first day of the fiscal quarter of the applicable scheduled vesting date.

Footnote F2

This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $52,500.